Polar Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Polar Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-89,500	Closed	-$11.1M	–	279
2018 Q4	$11.1M	Sell	89,500 -70,000	-44%	-$10.4M	0.12%	169
2018 Q3	$26.8M	Buy	159,500 +59,500	+60%	+$10.2M	0.23%	128
2018 Q2	$17.2K	Buy	100,000 +40,000	+67%	+$6.54M	0.1%	165
2018 Q1	$9.06M	Buy	+60,000	New	+$8.8M	0.09%	191
2017 Q4	–	Sell	-361,018	Closed	-$52.8M	–	262
2017 Q3	$52.8M	Buy	361,018 +128,500	+55%	+$19.4M	0.59%	46
2017 Q2	$36.2M	Buy	+232,518	New	+$35.6M	0.49%	70
2016 Q4	–	Sell	-8,500	Closed	-$1.03M	–	262
2016 Q3	$1.03M	Sell	8,500 -172,385	-95%	-$23.2M	0.02%	237
2016 Q2	$25.6M	Buy	+180,885	New	+$26.7M	0.48%	68
2015 Q4	–	Sell	-161,876	Closed	-$21.5M	–	279
2015 Q3	$21.5M	Buy	161,876 +18,763	+13%	+$3.23M	0.44%	79
2015 Q2	$25.2M	Buy	143,113 +1,054	+0.7%	+$189K	0.48%	66
2015 Q1	$24.5M	Buy	142,059 +3,611	+3%	+$620K	0.46%	71
2014 Q4	$22.7M	Buy	138,448 +60,294	+77%	+$10M	0.44%	68
2014 Q3	$12.5M	Buy	78,154 +75,650	+3,021%	+$11.6M	0.26%	122
2014 Q2	$368K	Buy	+2,504	New	+$347K	0.01%	254
2013 Q3	–	Sell	-147,046	Closed	-$10.1M	–	261
2013 Q2	$10.1M	Buy	+147,046	New	+$8.99M	0.35%	123

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Polar Capital's JAZZ Position: Q1 2019 in Review

Polar Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 89,500 shares — an estimated $11.1M sold.

Polar Capital first reported a position in JAZZ in Q2 2013 and held it in 15 quarters. The position peaked at $52.8M in Q3 2017. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

Polar Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Polar Capital sold 89,500 Jazz Pharmaceuticals shares in Q1 2019, an estimated $11.1M.
Polar Capital first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Polar Capital's Jazz Pharmaceuticals position peaked at $52.8M in Q3 2017.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Polar Capital's 13F filing for Q1 2019, filed 15 May 2019.